Using glycomics to predict liver transplant outcomes
Validation of Serum GLYcomics to Predict Graft Loss and Mortality After Liver Transplantation
This study is testing a new test that looks at sugars in the blood to see if it can help predict how well liver transplant patients will do in their first year after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Ghent Academic / other |
| Locations | 1 site (Ghent, Flanders) |
| Trial ID | NCT05866796 on ClinicalTrials.gov |
What this trial studies
This observational study aims to validate the GlycoTransplantTest, a prognostic biomarker, to predict graft loss and mortality in liver transplant recipients. The focus is on the critical first year post-transplant, where timely decision-making can significantly impact patient outcomes. By analyzing glycomic signatures from patients, the study seeks to improve the accuracy of predicting adverse post-transplant events. The research builds on previous findings from a pilot study conducted at Ghent University Hospital.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who are eligible for liver transplantation or are on the waiting list for liver transplantation.
Not a fit: Patients who are undergoing transplantation of organs other than the liver will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved decision-making for liver transplant patients, potentially reducing graft loss and mortality rates.
How similar studies have performed: Previous studies have shown promising results with glycomics in predicting transplant outcomes, but this multicentric validation is a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signed and dated patient informed consent document * Age ≥ 18 years * Ability to comply with protocol-specified evaluations and scheduled visits * Diagnosis of end-stage liver disease, primary hepatic malignancy meeting the Milan criteria for liver transplantation, or acute hepatic failure * Eligible for liver transplantation and/or active on the waiting list for liver transplantation. Individuals eligible and/or active on the waiting list for multiple organ transplantation including the liver (eg. Combined liver and kidney transplantation, or intestinal transplantation) are also eligible for inclusion. * Consulted the department of Gastroenterology and Hepatology at Ghent University Hospital Exclusion Criteria: \- Transplantation of one or more organs not including the liver
Where this trial is running
Ghent, Flanders
- Xavier Verhelst — Ghent, Flanders, Belgium (Recruiting)
Study contacts
- Study coordinator: Xavier Verhelst, MD, PhD
- Email: xavier.verhelst@uzgent.be
- Phone: 0032 9 332 23 71
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.